Back to news

Why ArriVent BioPharma (AVBP) Stock Is Down Today

Investivoq PriceTracker

ArriVent BioPharma (AVBP) is down 52.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp selloff appears tied to ArriVent’s update that its pivotal Phase 3 FURVENT trial for firmonertinib in first-line EGFR exon 20 insertion non-small cell lung cancer did not meet its primary endpoint. For a clinical-stage biotech, a miss in a late-stage study for a lead program can materially reduce expectations for approval, commercialization, and future valuation.

Details:

  • ArriVent said FURVENT failed to show a statistically meaningful progression-free survival benefit by blinded independent central review versus chemotherapy in the study’s primary analysis.
  • The company disclosed median progression-free survival of 11.0 months for firmonertinib 240 mg, 8.4 months for 160 mg, and 9.5 months for the control arm, with the 240 mg arm missing significance.
  • Management noted some favorable secondary measures, including progression-free survival by investigator assessment, objective response data, and an early trend in overall survival, but investors usually focus most heavily on the primary endpoint in pivotal trials.
  • The setback is especially important because ArriVent had previously highlighted FURVENT as a major late-stage catalyst, even though the company also said it had $373.1 million in cash and investments as of June 30, 2026, which it expected to fund operations into 2028.

    • Sources:

    ArriVent BioPharma, SEC, Nasdaq

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    EARLY ACCESS
    Receive AVBP Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $AVBP Hedge Fund Activity

    We have seen 98 institutional investors add shares of $AVBP stock to their portfolio, and 45 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • VIVO CAPITAL, LLC added 796,181 shares (+89.9%) to their portfolio in Q2 2026, for an estimated $27,659,327
    • BLACKROCK, INC. added 720,095 shares (+28.5%) to their portfolio in Q2 2026, for an estimated $25,016,100
    • LOGOS GLOBAL MANAGEMENT LP added 650,000 shares (+185.7%) to their portfolio in Q2 2026, for an estimated $22,581,000
    • AIHC CAPITAL MANAGEMENT LTD removed 644,788 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,399,935
    • D. E. SHAW & CO., INC. added 638,687 shares (+273.7%) to their portfolio in Q2 2026, for an estimated $22,187,986
    • FUND 1 INVESTMENTS, LLC removed 499,990 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $17,369,652
    • NOVO HOLDINGS A/S removed 442,142 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $15,360,013

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $AVBP Price Targets

    Multiple analysts have issued price targets for $AVBP recently. We have seen 2 analysts offer price targets for $AVBP in the last 6 months, with a median target of $44.0.

    Here are some recent targets:

    • Supawat Thongthip from Truist Securities set a target price of $45.0 on 05/29/2026
    • Yigal Nochomovitz from Citigroup set a target price of $43.0 on 05/13/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.